Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

75%

3 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 4
3(75.0%)
N/A
1(25.0%)
4Total
Phase 4(3)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT07273812Not ApplicableNot Yet Recruiting

Evaluating an AI-Based Mobile Application for Chemotherapy Support in Breast Cancer Patients

Role: collaborator

NCT06850571Phase 4Recruiting

Aflibercept and Bevacizumab for Diabetic Maculopathies

Role: collaborator

NCT04348006Phase 4Withdrawn

Assessment of Bortezomib (Alvocade ®) Efficacy and Safety in Newly Diagnosed Multiple Myeloma Patients

Role: collaborator

NCT04418986Phase 4Completed

Incisional Correction of Corneal Astigmatism During Phacoemulsification

Role: collaborator

All 4 trials loaded